Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $43.75.

A number of research firms recently weighed in on EYPT. Chardan Capital increased their price target on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Cantor Fitzgerald started coverage on Eyepoint Pharmaceuticals in a report on Wednesday, July 8th. They set an “overweight” rating and a $47.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective for the company. Royal Bank Of Canada decreased their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $12.66 on Thursday. The company has a market capitalization of $1.06 billion, a PE ratio of -3.62 and a beta of 1.73. The stock has a fifty day moving average of $13.21 and a 200-day moving average of $14.10. Eyepoint Pharmaceuticals has a one year low of $9.40 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%. As a group, research analysts forecast that Eyepoint Pharmaceuticals will post -3.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janus Henderson Group PLC acquired a new stake in Eyepoint Pharmaceuticals during the 4th quarter valued at $53,658,000. Commodore Capital LP acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter worth $36,414,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Eyepoint Pharmaceuticals in the third quarter worth $28,556,000. Orbimed Advisors LLC purchased a new position in shares of Eyepoint Pharmaceuticals during the third quarter valued at $25,575,000. Finally, Suvretta Capital Management LLC grew its holdings in shares of Eyepoint Pharmaceuticals by 26.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock valued at $143,012,000 after buying an additional 1,634,970 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.